Home>Topics>Funds>Biotech HOLDRs

Biotech HOLDRs BBH

  1. All
  2. Commentary
  3. Video Reports
  4. Fund Reports
  5. ETF Reports
  6. Headlines
    1. Biotechs don't have a friend in sight

      Headlines

      Thu, 10 Apr 2014

      high of $275.40. The index is now perched above the key support level of its 200-day moving average. If this week's decline holds it will mark the seventh straight on high volume. ETFs: XBI , BIB , BBH , FBT , PBE , BIS 5 comments!

    2. Momentum names tumbling again

      Headlines

      Thu, 10 Apr 2014

      and money is flowing into consumer stapes ( XLP +0.3% ) and utilities ( XLU +0.4% ). Biotech ETFs: IBB , XBI , BIB , BBH , FBT , PBE , BIS Nasdaq ETFs: QQQ , PSQ , TQQQ , QID , SQQQ , QLD , QQEW , QQQE , QQXT , TNDQ Small-cap ETFs: IWM , TZA

    3. Tech and biotech continue to slide

      Headlines

      Fri, 4 Apr 2014

      QQXT , RZG , JKJ , SBB , RSCO , UKK , VIOG , VTWG , TILT , FYX , FNDA , VIOV , XSLV , FYT , SKK , JKK , PXSV , EWRS , VTWV , TNDQ , TWOK , UVT , SMLV , SJH , IESM , FYC , VLU , PXSC , PXSG , IBB , XBI , BIB , BBH , FBT , PBE , BIS 1 comment!

    4. The One Sector Where Crash Helmets Are Advised

      Headlines

      Thu, 3 Apr 2014

      By Lou Basenese : For months, the experts have been duking it out about whether or not the biotech sector is in a full-blown bubble. In one corner, we have the Richard Bernsteins of the world. Even though the iShares Nasdaq Biotechnology Fund ( IBB ) essentially doubled in price over the last two

    5. Biotech Sell-Off Brings Value To U.S. Healthcare Stocks

      Headlines

      Tue, 25 Mar 2014

      By Morgan Myrmo: Over the past two years, biotechnology has been one of the most attractive industries to invest in, as returns have been nothing short of phenomenal. In terms of the domestic stock market, the U.S. S&P Biotechnology Select Industry Index has outperformed the S&P 500 heavily. ...

    6. Biotech sell-off continues

      Headlines

      Mon, 24 Mar 2014

      heavy volume in early trading. Modest support at 235 is holding. If it fails, the next point of resistance is ~225. Money flow has been decidedly negative for the past four weeks. ETFs: XBI , BIB , BBH , FBT , PBE , BIS Post your comment!

    7. FDA New Molecular Entities - Finding Them Ahead Of Approval But Also Ahead Of The Herd

      Headlines

      Tue, 18 Mar 2014

      By Intrepid Investor : In this article I discuss the value of New England Journal of Medicine (NEJM) as the single most reliable source information on clinical trials of important new drugs. I list the companies with the largest numbers of novel drugs or the most important ones that were approved

    8. Biotech Boom, Or Bubble?

      Headlines

      Fri, 14 Mar 2014

      By Franklin Templeton Investments : Evan McCulloch, CFA® Vice President/Research Analyst Portfolio Manager, Franklin Biotechnology Discovery Fund Franklin Equity Group® Currently, there are many exciting products in the pharmaceutical and biotech space producing clinical data that show a meaningful

    9. Alzheimer's Research Stocks - Technical And Other Considerations

      Headlines

      Fri, 7 Mar 2014

      By Pater Tenebrarum : Editor’s Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks. General Remarks on Our Approach to Biotechnology First off, we should point out that when it

    10. Jason Napodano Positions For 2014: Biotech M&A Growth Trend To Continue

      Headlines

      Tue, 31 Dec 2013

      By Jason Napodano : This is the sixth piece in Seeking Alpha's Positioning for 2014 series. This year we have once again asked experts on a range of different asset classes and investing strategies to offer their vision for the coming year and beyond. As always, the focus is on an overall approach

    « Prev12345Next »
    Content Partners